We are pleased to announce the publication of The Max Foundation’s 2019 Annual Report, showcasing the variety of achievements made possible with the support of our dedicated donors, partners, and global team.
“Looking back at 2019 a common theme stands out: reaching new frontiers,” write The Max Foundation CEO Pat Garcia-Gonzalez and The Max Foundation Board President Paula Boultbee in the report.
These new frontiers include our program’s expansion into Mozambique, where chronic myeloid leukemia (CML) patients gained access to lifesaving treatment for the first time. We also grew our access to diagnostics initiatives that allowed patients to have access to affordable and local molecular tests. And through our patient services, we connected with thousands of patients and their caregivers worldwide through one-on-one support and community outreach.
In this report, we celebrate our organization’s achievements as well as patients’ milestones—each with a unique journey toward accessing treatment and care.
We’re thrilled to share with you the significance of our growth into new frontiers, and the impact it’s had on the patients we support worldwide. We hope you see yourself in each of our achievements and feel how your support directly contributes to the lives of patients and families who are now able to face their cancer with dignity and hope.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
The African Organization for Research and Training in Cancer conference (AORTIC), happening November 5–8, 2019 brings together leading cancer specialists from around the world. During the conference, attendees are invited to join The Max Foundation and the International and Chronic Myeloid Leukemia Foundation (iCMLf) for an interactive session for African Physicians Treating CML. When: Wednesday,….
A new study led by Boston University School of Public Health, The Max Foundation, and Novartis Oncology found that chronic myeloid leukemia (CML) patients taking first-line treatment in low- and middle-income countries (LMICs) as part of the Glivec International Patient Assistance Program (GIPAP) have survival rates that compare favorably to those of CML patients receiving treatment in high-income countries.
In a recent commentary published in the Journal of Global Oncology, co-authors Pat Garcia-Gonzalez MA, Gilberto Lopes MD, Erin Schwartz and Lawrence Shulman MD, clearly outline the need and efficacy of humanitarian donation programs using lessons learned from the success of joint access initiatives between Novartis and The Max Foundation.
